206 related articles for article (PubMed ID: 36925069)
1. High Interobserver Variability Among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma.
Robert ME; Rüschoff J; Jasani B; Graham RP; Badve SS; Rodriguez-Justo M; Kodach LL; Srivastava A; Wang HL; Tang LH; Troncone G; Rojo F; Van Treeck BJ; Pratt J; Shnitsa I; Kumar G; Karasarides M; Anders RA
Mod Pathol; 2023 May; 36(5):100154. PubMed ID: 36925069
[TBL] [Abstract][Full Text] [Related]
2. Indirect Clinical Validation of a Programmed Death-Ligand 1 Laboratory-Developed Test for Gastric/Gastroesophageal Junction Adenocarcinoma with 22C3 Antibody Concentrate.
Kim JM; Kim B; Kim E; Jang M; Cho JH; Lee HS; Kwak Y; Huang L; Krishnan R; Bai SY; Mounawar M; Kim KM
Mol Diagn Ther; 2022 Nov; 26(6):679-688. PubMed ID: 36125657
[TBL] [Abstract][Full Text] [Related]
3. Multi-Institutional Study of Pathologist Reading of the Programmed Cell Death Ligand-1 Combined Positive Score Immunohistochemistry Assay for Gastric or Gastroesophageal Junction Cancer.
Fernandez AI; Robbins CJ; Gaule P; Agostini-Vulaj D; Anders RA; Bellizzi AM; Chen W; Chen ZE; Gopal P; Zhao L; Lisovsky M; Liu X; Shia J; Wang H; Yang Z; McCann L; Chan YG; Weidler J; Bates M; Zhang X; Rimm DL
Mod Pathol; 2023 May; 36(5):100128. PubMed ID: 36889057
[TBL] [Abstract][Full Text] [Related]
4. High interobserver and intraobserver reproducibility among pathologists assessing PD-L1 CPS across multiple indications.
Nuti S; Zhang Y; Zerrouki N; Roach C; Bänfer G; Kumar GL; Manna E; Diezko R; Kersch K; Rüschoff J; Jasani B
Histopathology; 2022 Dec; 81(6):732-741. PubMed ID: 35993150
[TBL] [Abstract][Full Text] [Related]
5. An artificial intelligence-powered PD-L1 combined positive score (CPS) analyser in urothelial carcinoma alleviating interobserver and intersite variability.
Lee KS; Choi E; Cho SI; Park S; Ryu J; Puche AV; Ma M; Park J; Jung W; Ro J; Kim S; Park G; Song S; Ock CY; Choe G; Park JH
Histopathology; 2024 Jul; 85(1):81-91. PubMed ID: 38477366
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 testing in metastatic triple-negative breast cancer: Interobserver and interplatform reproducibility of CE-IVD assays for CPS and IC scores.
Ivanova M; Frascarelli C; Cerbelli B; Pignataro MG; Pernazza A; Venetis K; Sajjadi E; Criscitiello C; Curigliano G; Guerini-Rocco E; Graziano P; Martini M; d'Amati G; Fusco N
Hum Pathol; 2024 Feb; 144():22-27. PubMed ID: 38278450
[TBL] [Abstract][Full Text] [Related]
7. Interobserver Agreement on the Interpretation of Programmed Death-ligand 1 (PD-L1) Combined Positive Score (CPS) Among Gynecologic Pathologists.
Mills AM; Bennett JA; Banet N; Watkins JC; Kundu D; Pinto A
Am J Surg Pathol; 2023 Aug; 47(8):889-896. PubMed ID: 37272261
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes and biomarker exploration of first-line PD-1 inhibitors plus chemotherapy in patients with low PD-L1-expressing of gastric or gastroesophageal junction adenocarcinoma.
Sun YT; Lu SX; Lai MY; Yang X; Guan WL; Yang LQ; Li YH; Wang FH; Yang DJ; Qiu MZ
Cancer Immunol Immunother; 2024 Jun; 73(8):144. PubMed ID: 38832979
[TBL] [Abstract][Full Text] [Related]
9. Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy.
Zhou KI; Peterson B; Serritella A; Thomas J; Reizine N; Moya S; Tan C; Wang Y; Catenacci DVT
Clin Cancer Res; 2020 Dec; 26(24):6453-6463. PubMed ID: 32820017
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 expression in paired biopsies and surgical specimens in gastric adenocarcinoma: A digital image analysis study.
Heo YJ; Kim B; Kim H; Kim S; Jang MS; Kim KM
Pathol Res Pract; 2021 Feb; 218():153338. PubMed ID: 33440275
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 Testing in Gastric Cancer by the Combined Positive Score of the 22C3 PharmDx and SP263 Assay with Clinically Relevant Cut-offs.
Park Y; Koh J; Na HY; Kwak Y; Lee KW; Ahn SH; Park DJ; Kim HH; Lee HS
Cancer Res Treat; 2020 Jul; 52(3):661-670. PubMed ID: 32019283
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 expression in gastric cancer: interchangeability of 22C3 and 28-8 pharmDx assays for responses to immunotherapy.
Ahn S; Kim KM
Mod Pathol; 2021 Sep; 34(9):1719-1727. PubMed ID: 34002009
[TBL] [Abstract][Full Text] [Related]
13. Inter- and intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma.
Downes MR; Slodkowska E; Katabi N; Jungbluth AA; Xu B
Histopathology; 2020 Jan; 76(2):191-200. PubMed ID: 31243779
[TBL] [Abstract][Full Text] [Related]
14. FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1.
Fashoyin-Aje L; Donoghue M; Chen H; He K; Veeraraghavan J; Goldberg KB; Keegan P; McKee AE; Pazdur R
Oncologist; 2019 Jan; 24(1):103-109. PubMed ID: 30120163
[TBL] [Abstract][Full Text] [Related]
15. Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer.
Kulangara K; Zhang N; Corigliano E; Guerrero L; Waldroup S; Jaiswal D; Ms MJ; Shah S; Hanks D; Wang J; Lunceford J; Savage MJ; Juco J; Emancipator K
Arch Pathol Lab Med; 2019 Mar; 143(3):330-337. PubMed ID: 30028179
[TBL] [Abstract][Full Text] [Related]
16. Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer.
Lei M; Siemers NO; Pandya D; Chang H; Sanchez T; Harbison C; Szabo PM; Janjigian Y; Ott PA; Sharma P; Bendell J; Evans TRJ; de Braud F; Chau I; Boyd Z
Clin Cancer Res; 2021 Jul; 27(14):3926-3935. PubMed ID: 33782030
[TBL] [Abstract][Full Text] [Related]
17. Evaluating programmed death-ligand 1 (PD-L1) in head and neck squamous cell carcinoma: concordance between the 22C3 PharmDx assay and the SP263 assay on whole sections from a multicentre study.
Cerbelli B; Girolami I; Eccher A; Costarelli L; Taccogna S; Scialpi R; Benevolo M; Lucante T; Luigi Alò P; Stella F; Gemma Pignataro M; Fadda G; Perrone G; D'Amati G; Martini M
Histopathology; 2022 Jan; 80(2):397-406. PubMed ID: 34496080
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological features of PD-L1 protein expression, EBV positivity, and MSI status in patients with advanced gastric and esophagogastric junction adenocarcinoma in Japan.
Yoshida T; Ogura G; Tanabe M; Hayashi T; Ohbayashi C; Azuma M; Kunisaki C; Akazawa Y; Ozawa S; Matsumoto S; Suzuki T; Mitoro A; Fukunaga T; Shimizu A; Fujimoto G; Yao T
Cancer Biol Ther; 2022 Dec; 23(1):191-200. PubMed ID: 35220884
[TBL] [Abstract][Full Text] [Related]
19. Scoring PD-L1 Expression in Urothelial Carcinoma: An International Multi-Institutional Study on Comparison of Manual and Artificial Intelligence Measurement Model (AIM-PD-L1) Pathology Assessments.
Rüschoff J; Kumar G; Badve S; Jasani B; Krause E; Rioux-Leclercq N; Rojo F; Martini M; Cheng L; Tretiakova M; Mitchell C; Anders RA; Robert ME; Fahy D; Pyle M; Le Q; Yu L; Glass B; Baxi V; Babadjanova Z; Pratt J; Brutus S; Karasarides M; Hartmann A
Virchows Arch; 2024 Apr; 484(4):597-608. PubMed ID: 38570364
[TBL] [Abstract][Full Text] [Related]
20. Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer.
Noske A; Wagner DC; Schwamborn K; Foersch S; Steiger K; Kiechle M; Oettler D; Karapetyan S; Hapfelmeier A; Roth W; Weichert W
Breast; 2021 Dec; 60():238-244. PubMed ID: 34768219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
